Related Experiment Video

Updated: May 25, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Nilotinib as first-line therapy for chronic myeloid leukemia

A Vaid1

  • 1Department of Medical Oncology, Cancer Institute, Medanta Hospital, Medicity, Sector 38, Gurgaon, NCR, Delhi, India. akvaid@yahoo.com

Indian Journal of Cancer
|February 2, 2012
PubMed

Insights

Tyrosine Kinase Inhibitors revolutionized chronic myeloid leukemia treatment, offering long-term survival. Nilotinib shows promise as a first-line therapy, addressing imatinib resistance and improving patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Background:

  • Tyrosine Kinase Inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) management.
  • Long-term disease-free survival is now achievable for most CML patients.
  • Imatinib resistance necessitates exploration of alternative targeted therapies.

Purpose of the Study:

  • To review the clinical data and efficacy of nilotinib.
  • To assess the role of nilotinib in the first-line treatment of CML.
  • To understand nilotinib's position in the evolving landscape of CML therapy.

Main Methods:

  • Review of clinical trial data and published literature on nilotinib in CML.
  • Analysis of efficacy and safety profiles of nilotinib, particularly in first-line settings.
  • Comparison of nilotinib with existing CML treatment paradigms.

Main Results:

  • Nilotinib demonstrates mature data supporting its efficacy.
  • The drug shows significant promise even when used as a first-line therapy.
  • Nilotinib addresses challenges posed by imatinib resistance.

Conclusions:

  • Nilotinib is a valuable therapeutic option in the first-line management of chronic myeloid leukemia.
  • Its established data supports its role in achieving long-term disease control.
  • Nilotinib represents a key advancement in targeted therapy for CML.

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...